Physician profile
Allison Frere
NPI 1033871421
$1,698.29
in general payments reported to CMS, 2019-2025
23 companies · $155 in 2025
The $155 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $47.92 · 2023: $189 · 2024: $1,306 · 2025: $155.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,362 · Travel and Lodging: $289.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,361.65 |
| Travel and Lodging | $288.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $631.57 | 2024 | Watchman Flx |
| Actelion Pharmaceuticals US, INC. | $243.44 | 2024 | Opsumit, Uptravi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $140.93 | 2023-2024 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $140.18 | 2024-2025 | Wainua |
| Amgen INC. | $83.01 | 2023-2025 | Repatha, Tezspire, Repatha |
| Medtronic, INC. | $54.73 | 2024 | Onyx Frontier |
| Novartis Pharmaceuticals Corporation | $46.17 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $39.22 | 2023 | Verquvo, Belsomra |
| Argenx US, INC. | $36.75 | 2022-2023 | Vyvgart |
| Astellas Pharma US INC | $34.31 | 2025 | Cresemba |
| Atricure, INC. | $25.71 | 2022 | |
| Ardelyx, INC. | $23.64 | 2024 | Ibsrela |
| Abbvie INC. | $23.13 | 2024 | |
| Pfizer INC. | $22.88 | 2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $21.51 | 2024 | Lifevest |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $21.24 | 2023 | Veltassa |
| Bayer Healthcare Pharmaceuticals INC. | $17.81 | 2024 | |
| Abbott Laboratories | $16.65 | 2025 | Infinity |
| Janssen Pharmaceuticals, INC | $16.58 | 2023 | Xarelto |
| Exact Sciences Corporation | $15.31 | 2025 | Cologuard Collection Kit |
| Novo Nordisk INC | $14.83 | 2023 | |
| Supernus Pharmaceuticals, INC. | $14.65 | 2025 | Qelbree |
| Biogen, INC. | $14.04 | 2023 | Vumerity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allison Frere listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.